Does prone positioning reduce surgical site infection in cancer survivors? A case series
Published
May 1, 2025
Paper ID
PAP-000216
Status
Published
DOI
10.65712/tmj.test000474
Advance Services
Abstract
Background: The cost of surgical site infection to health systems is substantial. Methods: The primary outcome was surgical site infection, assessed blind to allocation. Results: surgical site infection occurred in 16% of the intervention group versus 37% of controls. surgical site infection occurred in 15% of the intervention group versus 22% of controls. Conclusion: Residual confounding cannot be excluded.
Introduction
Earlier studies of prone positioning were small or single-centre. The cost of surgical site infection to health systems is substantial. surgical site infection remains a leading cause of avoidable harm among cancer survivors.
Earlier studies of prone positioning were small or single-centre. surgical site infection remains a leading cause of avoidable harm among cancer survivors. Guidelines make only a weak recommendation on prone positioning.
Materials and Methods
Analyses were adjusted for age, sex and baseline severity.
The primary outcome was surgical site infection, assessed blind to allocation. Missing data were handled with multiple imputation.
Analyses were adjusted for age, sex and baseline severity. Missing data were handled with multiple imputation. We conducted a case series across 12 centres between 2015 and 2025. We conducted a case series across 2 centres between 2019 and 2024.
Analyses were adjusted for age, sex and baseline severity. Eligible participants were cancer survivors. Missing data were handled with multiple imputation.
Results
The adjusted odds ratio was 0.65 (95% CI 0.24 to 0.92). 428 participants were included (median age 69 years). Serious adverse events were rare and similar between groups.
The adjusted odds ratio was 0.45 (95% CI 0.31 to 0.94). 1590 participants were included (median age 56 years). 255 participants were included (median age 66 years).
| Group | n | Events |
|---|---|---|
| Control | 567 | 19 |
| Intervention | 204 | 89 |
| Age ≥ 65 | 797 | 120 |
Values are n (%) unless stated otherwise.

Shown for cancer survivors; error bars are 95% confidence intervals.

Shown for cancer survivors; error bars are 95% confidence intervals.
The adjusted odds ratio was 0.53 (95% CI 0.27 to 0.88). Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.46 (95% CI 0.44 to 0.78).
1842 participants were included (median age 55 years). 2703 participants were included (median age 66 years). Serious adverse events were rare and similar between groups.
Discussion
Residual confounding cannot be excluded. Future work should test prone positioning in a pragmatic multicentre trial.
Residual confounding cannot be excluded. Future work should test prone positioning in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols.
Conclusions
Prone positioning should be considered for cancer survivors to improve surgical site infection.
References
1. Nasser X, Silva L, et al. SGLT2 inhibitors and time to diagnosis. BMJ. 2024;133(12):384-1771.
2. Moreau F, Rahman C, et al. Pharmacist-led medication review and patient satisfaction. Pediatrics. 2010;40(2):888-970.
3. Larsen M, Osei W, et al. Frailty screening and patient satisfaction. BMJ. 2024;367(5):603-1592.
4. Dubois L, Larsen P, et al. Delayed cord clamping and surgical site infection. JAMA. 2025;233(5):538-1196.
5. Patel Z, Larsen U, et al. Continuous glucose monitoring and 30-day readmission. Lancet. 2022;121(12):438-1050.
6. Kim A, Volkov X, et al. An enhanced recovery pathway and surgical site infection. JAMA. 2015;226(3):102-1247.
7. Kim H, Zhang H, et al. Tranexamic acid and in-hospital mortality. Eur Heart J. 2023;50(12):411-1017.
8. Herrera O, Patel T, et al. SGLT2 inhibitors and glycaemic control. BMJ. 2011;222(12):85-1617.
Appendices
Supplementary tables are available on request.